Nobel Prize 2025 in Medicine

Nobel Prize 2025 in Medicine: Breakthrough Discovery in Immune Tolerance

The Nobel Prize 2025 in Medicine or physiology  has been awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries concerning peripheral immune tolerance. Their research has fundamentally transformed our understanding of how the immune system maintains balance and prevents autoimmune diseases while effectively fighting infections.

The Laureates

Mary E. Brunkow (born 1961) is a senior program officer at the Institute for Systems Biology in Seattle, Washington. Fred Ramsdell (born 1960) serves as a scientific consultant for Sonoma Biotherapeutics in San Francisco. Shimon Sakaguchi (born 1951) is a professor at the Immunology Research Center at Osaka University in Japan.

Revolutionary Research in Immune Tolerance

The Challenge: Understanding Immune Balance

The human immune system faces a complex challenge every day: distinguishing between harmful foreign invaders and the body’s own healthy tissues. While the immune system must be powerful enough to combat thousands of different microbes, it must also be precisely controlled to prevent attacking the body’s own organs—a phenomenon that would lead to autoimmune diseases.

Previously, researchers believed that immune tolerance was primarily achieved through central tolerance, a process occurring in the thymus where potentially harmful immune cells are eliminated during development. However, this process is only 60-70% efficient, leaving many self-reactive T cells in circulation.

Sakaguchi’s Pioneering Discovery (1995)

In 1995, Shimon Sakaguchi challenged conventional wisdom by discovering a previously unknown class of immune cells that actively suppress immune responses. Swimming against the scientific tide of his time, Sakaguchi identified regulatory T cells (Tregs)—specialized immune cells that act as “security guards” of the immune system.

Through elegant experiments involving mice whose thymus had been removed, Sakaguchi demonstrated that certain T cells carrying both CD4 and CD25 surface proteins could prevent autoimmune diseases. These cells, later termed regulatory T cells, actively suppress overaggressive immune responses and maintain immune homeostasis.

Brunkow and Ramsdell’s Genetic Breakthrough (2001)

Mary Brunkow and Fred Ramsdell made the second crucial discovery in 2001 while investigating a strain of sick male mice known as “scurfy” mice. These mice suffered from severe autoimmune diseases, and through painstaking genetic analysis, the researchers identified the cause: a mutation in a gene they named FOXP3.

Crucially, they discovered that mutations in the human equivalent of the FOXP3 gene cause IPEX syndrome (Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked), a rare but devastating autoimmune disease affecting male infants. This finding directly linked their mouse research to human disease, demonstrating the clinical relevance of their discovery.

Connecting the Discoveries (2003)

Two years later, Sakaguchi made the final connection by proving that the FOXP3 gene governs the development and function of regulatory T cells. This revelation unified the previous discoveries, showing that FOXP3 acts as a “master regulator” of Treg cells, controlling their ability to suppress immune responses.

The FOXP3 Gene and Regulatory T Cells

Molecular Mechanisms

FOXP3 (forkhead box P3), also known as scurfin, is a transcription factor that functions as the master switch for regulatory T cell development. Located on the X chromosome, mutations in this gene lead to the absence or dysfunction of regulatory T cells, resulting in uncontrolled immune activation.

The protein works by binding to DNA and regulating the expression of genes crucial for Treg function. It both enhances genes beneficial to regulatory function and suppresses genes that would be harmful, such as those promoting inflammation.

Clinical Significance: IPEX Syndrome

IPEX syndrome provides a stark illustration of what happens when the FOXP3 gene is defective. Affected male infants develop:

• Severe autoimmune enteropathy causing intractable diarrhea

• Type 1 diabetes often appearing in the first month of life

• Severe eczema and dermatitis

• Multiple autoimmune endocrinopathies

Without treatment, IPEX syndrome is often fatal by age 2-3, but bone marrow transplantation can be life-saving by providing functional regulatory T cells.

Peripheral Immune Tolerance Explained

Peripheral immune tolerance represents a sophisticated backup system that operates after immune cells mature and leave primary lymphoid organs. Unlike central tolerance, which occurs during immune cell development, peripheral tolerance actively manages immune responses in tissues throughout the body.

The key mechanisms include:

• Regulatory T cell suppression – Active inhibition of overactive immune responses

• Clonal deletion – Elimination of self-reactive cells in secondary lymphoid organs

• Anergy induction – Rendering potentially harmful cells functionally inactive

• Immune deviation – Redirecting immune responses toward less harmful pathways

Therapeutic Implications and Future Applications

Autoimmune Disease Treatment

The discovery of regulatory T cells has opened new therapeutic avenues for treating autoimmune diseases such as multiple sclerosis, Type 1 diabetes, inflammatory bowel disease, and rheumatoid arthritis. Researchers are developing strategies to enhance Treg function or transfer functional Tregs to patients.

Cancer Immunotherapy

Understanding regulatory T cells has also revolutionized cancer treatment approaches. While Tregs normally prevent autoimmunity, in cancer they can inappropriately suppress anti-tumor immune responses. Modern immunotherapies often work by reducing Treg activity in tumors, allowing the immune system to better attack cancer cells.

Organ Transplantation

The research promises to improve organ transplantation outcomes by potentially inducing long-term tolerance to transplanted organs without requiring lifelong immune suppression. This could dramatically reduce transplant rejection and associated complications.

Scientific Impact and Recognition

The Nobel Committee emphasized that these discoveries “have been decisive for our understanding of how the immune system functions and why we do not all develop serious autoimmune diseases”. The research has:

• Established an entirely new field of peripheral immune tolerance research

• Led to over 270 citations for key regulatory T cell research papers

• Inspired numerous clinical trials for autoimmune diseases and cancer

• Provided fundamental insights into immune system regulation across species

Marie Wahren-Herlenius, a rheumatology professor at the Karolinska Institute, noted that this research explains “how we keep our immune system under control so we can fight all imaginable microbes and still avoid autoimmune disease”.

Nobel Prize in Medicine: Last Five Years